‌

US Patent 10865242 Method and compositions for cellular immunotherapy

Patent 10865242 was granted and assigned to Seattle Children's on December, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Seattle Children's

Current Assignee

Seattle Children's

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

108652420

Date of Patent

December 15, 2020

Patent Application Number

153024030

Date Filed

April 8, 2015

Patent Citations

‌

US Patent 10266592 Drug regulated transgene expression

Patent Citations Received

‌

US Patent 11884729 Anti-L1CAM antibodies and uses thereof

Patent Primary Examiner

Quang Nguyen

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10865242 Method and compositions for cellular immunotherapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API